Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells by Liu, Shengzhi et al.
Osteocyte-Driven Downregulation of Snail Restrains Effects of 
Drd2 Inhibitors on Mammary Tumor Cells
Shengzhi Liu1,2, Yao Fan1,2, Andy Chen2, Aydin Jalali2, Kazumasa Minami3, Kazuhiko 
Ogawa3, Harikrishna Nakshatri4, Bai-Yan Li1, and Hiroki Yokota1,2
1Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin 150081, 
China
2Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, 
Indianapolis, IN 46202, USA
3Department of Radiation Oncology, Osaka University Graduate School of Medicine Suita, Osaka 
565-0871, Japan
4Department of Surgery, Simon Cancer Research Center, Indiana University School of Medicine, 
Indianapolis, IN 46202, USA
Abstract
While bone is a frequent target of breast cancer-associated metastasis, little is known about the 
effects of tumor-bone interactions on the efficacy of tumor-suppressing agents. Here we examined 
the effect of two FDA-approved dopamine modulators, Fluphenazine (FP) and Trifluoperazine 
(TFP), on mammary tumor cells, osteoclasts, osteoblasts, and osteocytes. These agents suppressed 
proliferation and migration of mammary tumor cells chiefly by antagonizing dopamine receptor 
D2 and reduced bone resorption by downregulating nuclear factor of activated T-cells, cytoplasmic 
1 (Nfatc1). Three-dimensional spheroid formation assays revealed that tumor cells have high 
affinity to osteocytes and type I collagen, and interactions with osteocytes as well as 
administration of FP and TFP downregulated Snail and suppressed migratory behaviors. Unlike 
the inhibitory action of FP and TFP on tumor growth, tumor-osteocyte interactions stimulated 
tumor proliferation by upregulating NFκB and Akt. In the bone microenvironment, osteocytes 
downregulated Snail and acted as an attractant as well as a stimulant to mammary tumor cells. 
These results demonstrate that tumor-osteocyte interactions strengthen dopamine receptor-
mediated suppression of tumor migration but weaken its inhibition of tumor proliferation in the 
osteocyte-rich bone microenvironment.
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Introduction
Bone is a frequent site of metastasis from cancers, as the bone microenvironment provides a 
rich bed of various hormones and cytokines for tumor growth (1). It is reported that 
transforming growth factor beta (TGF-β) and its associated pathway drive a vicious cycle for 
tumor growth and bone resorption (2). Bone consists of many types of cells, including 
hematopoietic and mesenchymal stem cells in bone marrow, as well as bone-forming 
osteoblasts, bone-resorbing osteoclasts, and osteocytes, the most abundant cell type in the 
bone matrix (3,4). Among bone marrow-derived cells of hematopoietic origin, T cells 
produce TGF-β and receptor activator of nuclear factor kappa B ligand (RANKL), which 
activate differentiation of macrophages to bone-resorbing osteoclasts (5). While the 
interactions of tumor cells with osteoclasts in the presence of TGF-β, RANKL, and 
interleukins have been extensively studied (6–8), interactions between tumor cells and 
osteocytes, which are thought to be a sensor for mechanotransduction (9), have not been 
fully explored.
In this study, we focused on two FDA-approved drugs, Fluphenazine (FP) and 
Trifluoperazine (TFP), and evaluated their roles in tumor-bone interactions. These two 
agents are modulators of dopaminergic signaling and currently used as antipsychotic 
medications (10,11). The dopamine system is involved in many neurological functions (12), 
but it is also important in other tissues, such as the cardiovascular and skeletal systems 
(13,14). Dopaminergic signaling is mediated via G protein-coupled dopamine receptors (D1, 
D2, D3, D4, and D5), and regulates voluntary movements and reward responses (15). This 
pathway is integral for many neural functions, and its deficiency causes neurological and 
psychiatric disorders such as Parkinson’s disease and schizophrenia (16). Dopaminergic 
signaling has recently been shown to be a potential target for preventing mammary tumor 
growth and bone metastasis using A77636, an agonist of DRD1 (17). Unlike FP and TFP, 
A77636 is not an FDA-approved drug. Furthermore, little is known about the effects of FP 
and TFP on tumor-bone interactions. In this study, we investigated their effects on mammary 
tumor cells, as well as bone-resorbing osteoclasts, bone-forming osteoblasts, and mechano-
sensing osteocytes. Dopamine is reported to promote proliferation of bone-forming 
osteoblasts and mineralization of bone tissue (18).
To examine the efficacy of FP and TFP as well as interactions of mammary tumor cells with 
osteoclasts and osteocytes, we employed three dimensional (3D) spheroid cultures as well as 
monolayer cell cultures (19,20). Interactions of tumor cells with bone cells were examined 
by pre-mixing tumor and bone cells and forming a mosaic spheroid or fusing a pair of 
separately prepared spheroids consisting of tumor cells alone and bone cells alone. While we 
formed spheroids from 4T1.2 mammary tumor cells (21), RAW267.4 pre-osteoclast cells 
(22), MC3T3 osteoblast-like cells (23), and MLO-A5 osteocyte-like cells (24), our analysis 
of bone-tumor interactions was mostly focused on MLO-A5 cells in the presence and 
absence of FP and TFP. We used confocal microscopy to examine cellular morphology and 
viability of fluorescently labeled spheroids.
We hypothesized that FP and TFP suppress tumor growth and tumor-associated bone 
resorption via dopamine receptors. Since bone is one of the most frequent sites of metastasis 
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from breast cancer, interactions of tumor cells with the most abundant cells in bone matrix is 
our research aim. We further hypothesized that tumor-osteocyte interactions may favor 
immobilization of tumor cells in the bone microenvironment and restrain efficacy of DRD2 
inhibitors. Dopamine receptors are members of the DRD1-like family (DRD1 and DRD5) or 
DRD2-like family (DRD2, DRD3, and DRD4). To evaluate the role of DRD1-like and 
DRD2-like receptors in the responses to FP and TFP, we employed siRNAs specific to these 
receptors. In bone-tumor interactions, we focused on the role of Snail, a transcription factor 
involved in the epithelial-to-mesenchymal transition (EMT) (25), ZO-1 (zonula occludens 
1), as well as NFκB and AKT, two factors involved in tumor progression. ZO-1 is a tight 
junction-associated signaling protein, which mediates cell adhesion and is downregulated in 
EMT (26).
To evaluate direct and indirect tumor-bone interactions, we employed osteocyte-derived 
conditioned medium as well as a tumor-bone spheroid fusion assay. We examined the effects 
of secretory factors from osteocytes on tumor proliferation and tested the linkage of bone-
tumor interactions to mesenchymal-to-epithelial transition (MET, a reversal of EMT) by 
determining and over-expressing Snail by plasmid transfection. Induction of MET at a 
potential site of metastasis for breast cancer cells has significant implications in regulating 
invasion and colonization of tumor cells in the bone microenvironment. These assays 
allowed us to evaluate the potential mechanism underlying bone-tumor interactions and their 
impact on the efficacy of FP and TFP. The results demonstrate that type I collagen and Snail 
play crucial roles in tumor-osteocyte interactions to enhance FP’s and TFP’s suppression of 
tumor migration and reduce their attenuation of tumor proliferation.
Materials and Methods
Cell culture
4T1.2 mouse mammary tumor cells (obtained from Dr. R. Anderson at Peter MacCallum 
Cancer Institute, Melbourne, Australia) were cultured in DMEM. RAW264.7 pre-osteoclast 
cells (ATCC TIB-71, Manassas, VA, USA), MC3T3 osteoblast-like cells (Sigma-Aldrich, St. 
Louis, MO, USA), and MLO-A5 osteocyte-like cells (obtained from Dr. L. Bonewald at 
Indiana University, IN, USA) were grown in αMEM. Mycoplasma testing was conducted 
using a Lonza mycoalert plus mycoplasma kit (Lonza Inc., Morristown, NJ, USA). For 
4T1.2 cells, cell authentication testing was conducted using whole exome DNA sequencing 
(Agilent SureSelect Mouse Exon, Santa Clara, CA, USA). The culture media was 
supplemented with 10% fetal bovine serum and antibiotics, and cells were maintained at 
37°C and 5% CO2. Fluphenazine (FP; Sigma-Aldrich) and Trifluoperazine (TFP; Enzo Life 
Sciences, Farmingdale, NY, USA) were employed as modulators of dopaminergic signaling. 
Fluphenazine (438 Da) and Trifluoperazine (407 Da) are small synthetic agents used as 
antipsychotic medications in the treatment of schizophrenia. 4T1.2 cells were also treated 
with type I collagen (Corning, NY, USA). Cellular proliferation was examined using an 
MTT cell proliferation assay (Invitrogen, Carlsbad, CA, USA) with the procedure previously 
described (17).
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Transfection of Snail plasmid and siRNA for dopamine receptors D1 and D2 (DRD1 and 
DRD2)
For overexpressing Snail protein, 4T1.2 tumor cells were transfected with a plasmid 
consisting of Snail coding sequence (SnailHA_pcDNA3; Addgene, Cambridge, MA, USA), 
while a blank plasmid vector (FLAG-HA-pcDNA3.1; Addgene) was used as a control. 4T1.2 
cells were also treated with siRNA specific to Drd1 (Life Technologies; siRNA: s65128) and 
Drd2 (161556). As a nonspecific control, a negative siRNA (Silencer Select #1, Life 
Technologies) was used. Cells were transiently transfected with siRNA in Opti-MEM I 
medium with Lipofectamine RNAiMAX (Life Technologies). Twenty-four hours later, the 
medium was replaced by regular culture medium with reagents. The efficiency of silencing 
was assessed with immunoblotting 24 h after transfection.
Two-dimensional motility assay
A wound healing scratch motility assay was utilized to evaluate 2-dimensional cell motility 
(27). In brief, cells were grown on 12-well plates, and a plastic tip was used to scratch a gap 
onto the cell layer. After incubation, the areas newly occupied with cells in the scratched 
zone were imaged and measured with Image J (National Institutes of Health, Maryland, 
USA).
Osteoclast differentiation assay
Using RAW264.7 pre-osteoclast cells, an osteoclast differentiation assay was conducted in 
96-well plates (28). During 6-day experiments growing cells in 20 ng/ml of RANKL, the 
culture medium was exchanged once on day 4. Adherent cells were fixed and stained with a 
tartrate resistant acid phosphate (TRAP)-staining kit (Sigma-Aldrich, Missouri, USA), 
according to the manufacturer’s instructions. TRAP-positive multinucleated cells (> 3 
nuclei) were identified as mature osteoclasts and counted.
Western blot analysis
Cells were lysed with a radio-immunoprecipitation assay buffer supplemented with protease 
inhibitors (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and phosphatase inhibitors 
(Calbiochem, Billerica, MA, USA). Isolated proteins were fractionated using 10-15% SDS 
gels and electro-transferred to polyvinylidene difluoride membranes (Millipore, Billerica, 
MA, USA). We used antibodies against Atf4, p-Akt, Akt, caspase 3, cathepsin K, eIF2α, p-
eIF2α, lamin B, Lc3A/B II, Nfatc1, NFκB, p-NFκB, Snail, Zo-1 (Cell Signaling, Danvers, 
MA, USA), and β-actin (Sigma). Protein levels were assayed using a SuperSignal west 
femto maximum sensitivity substrate (Thermo Scientific, Waltham, MA, USA).
Formation and viability of 3D spheroids
Cells were cultured in Ultra-low attachment 96-well plates (S-BIO, New Hampshire, USA) 
at 1×104 cells/well for 4T1.2 cells, 2×104 cells/well for A5 cells, 2×104 cells/well for RAW 
cells. Cells were imaged every 24 h, and area and roughness were calculated with ImageJ. 
To observe spheroid formation of mixtures of cancer cells with osteocyte and osteoblast 
cells, IncuCyte ZOOM real-time imaging microscope was used to image cells every hour 
with fluorescent staining (Incucyte CytoLight Green and Red, Essen Bioscience, Michigan, 
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USA). In combination, 4T1.2, A5, and RAW cells were seeded at 1×104 cells/well, 3×103 
cells/well, and 2×103 cells/well, respectively. A three-dimensional spheroid viability assay 
was conducted by plating 4T1.2, MLO-A5 and RAW 264.7 cells on ultra-low attachment 
96-well plates at concentrations of 1×104, 2×104, and 2×104 cells/well, then incubated for 
24 h. Treatment medium was exchanged, and spheroids were incubated for 72 h. The cell 
viability was measured with CellTiter-Glo® 3D Cell Viability Assay (Promega). To 
visualize 3D spheroid proliferation in response to medium exchange and drug treatment, a 
fluorescence-based cell proliferation kit was used (Click-iT™ EdU Alexa Fluor™ 488 
Imaging Kit; Thermo-Fisher). After 24 h, cells were incubated with EdU for 3 h, then fixed 
and labeled, per manufacturer’s instruction. Confocal microscope images were acquired 
with FV1000 (Olympus, Tokyo, Japan) and analyzed using ImageJ.
Animal models
The experimental procedures using animals were approved by the Indiana University 
Animal Care and Use Committee and were in compliance with the Guiding Principles in the 
Care and Use of Animals endorsed by the American Physiological Society. Mice were 
housed five per cage and provided with mouse chow and water ad libitum. In the mouse 
model of mammary tumor (29), 23 BALB/c female mice (~6 weeks, Harlan Laboratories) 
received subcutaneous injections of 4T1.2 cells (5.0 × 105 cells in 50 μl PBS) to the 
mammary fat pad on day 1. FP or TFP (1 mg/kg body weight) was administered 
subcutaneously into the area of cell injection every day, while the placebo animals received a 
vehicle control. The animals were sacrificed on day 18, and the weight of each tumor was 
measured. In the mouse model of bone metastasis (30), 33 BALB/c female mice received 
injection of 4T1.2 cells (1.0 × 105 cells in 50 μl PBS) to the right iliac artery. FP or TFP was 
administered daily via i.p. injection at 2 mg/kg body weight, and the animals were sacrificed 
on day 17. A whole body X-ray of each mouse was taken, and the tibia and femur were 
harvested for mechanical testing, μCT imaging, and histology. To examine the role of type I 
collagen in the bone microenvironment, 10 BALB/c female mice were employed, and type I 
collagen was co-injected with 4T1.2 cells (5 × 105 cells in 20 μl PBS with 50 μg/ml type I 
collagen) into the intra-tibial cavity.
μCT imaging
Micro-computed tomography was performed using Skyscan 1172 (Bruker-MicroCT, 
Kontich Belgium) (31). The harvested bone samples were wrapped in parafilm to maintain 
hydration and placed in a plastic tube and oriented vertically. Scans were performed at pixel 
size 8.99 μm. Using manufacturer-provided software, the images were reconstructed 
(nRecon v1.6.9.18) and analyzed (CTan v1.13).
Mechanical testing and histology
Mechanical testing was conducted using an ElectroForce loading device (TA Instruments, 
Eden Prairie, MN, USA). A sinusoidal force (1 N peak-to-peak force) was applied at 1 Hz, 
and the slope of force-displacement relationship was determined as tibial stiffness. For 
histology, bone samples were fixed in 10% neutral buffered formalin and decalcified in a 
14% EDTA solution. They were then dehydrated through a series of graded alcohols, cleared 
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in xylene, and embedded in paraffin. H&E staining was conducted on the sagittal sections, 
and the distribution of tumor cells in the tibial bone cavity was determined.
Statistical analysis
The data were expressed as mean ± standard deviation. One-way analysis of variance was 
employed to examine statistical significance among groups, and Fisher’s protected least 
significant difference was conducted post hoc to evaluate pairwise comparisons. Statistical 
significance for p < 0.05 was assumed.
Results
Inhibition of proliferation and differentiation of RAW264.7 pre-osteoclast cells
In order to evaluate the effects of FP and TFP on bone-resorbing osteoclasts, we conducted 
in vitro analysis using RAW264.7 pre-osteoclast cells. First, the relative proliferation of 
RAW264.7 cells using an MTT cell proliferation assay was significantly decreased by FP in 
a dose-dependent manner (Fig. 1A). Second, in response to RANKL-driven 
osteoclastogenesis, the phosphorylation level of eIF2α was elevated, and genes related to 
osteoclast function, such as NFATc1 and Cathepsin K, were downregulated by treatment 
with 1, 5, and 10 μM FP (Fig. 1B&C). The same trends were observed by TFP treatment 
(Fig. 1D-F). Third, the number of TRAP-positive, multi-nucleated cells induced by RANKL 
administration was decreased by FP and TFP (Fig. 1G&H). Lastly, 3D viability of 
RAW264.7 spheroids was significantly reduced by 10 and 20 μM TFP (Fig. 1I&J). 
Collectively, the result showed that FP and TFP inhibited proliferation and differentiation of 
RAW264.7 pre-osteoclast cells.
To evaluate the effects of FP and TFP on bone formation, we also examined bone-forming 
osteoblasts (MC3T3 osteoblast-like cells), as well as osteocytes (MLO-A5 osteocyte-like 
cells). Unlike their inhibitory effect to RAW264.7 cells, 5 μM FP and TFP did not 
significantly reduce proliferation of MC3T3 cells (Supplementary Fig. S1A). These agents 
elevated the protein levels of p-eIF2α and Atf4, a transcription factor important for bone 
formation (Supplementary Fig. S1B). Furthermore, they elevated osteoprotegerin (Opg) 
mRNA and osteocalcin (Ocn) mRNA (Supplementary Fig. S1C). Opg is an inhibitory factor 
of osteoclastogenesis, while Ocn is a marker for bone formation. The same trends in cell 
proliferation and protein expression were found in MLO-A5 cells (Supplementary Fig. 
S1D&E). In a 3D spheroid formation assay, the agents did not reduce spheroid size or 
luminescence-based survival of MC3T3 and MLO-A5 cells (Supplementary Fig. S1F&G).
Inhibitory effects on proliferation and migration of 4T1.2 mammary tumor cells
Thus far, the results with RAW264.7 cells, MC3T3 cells, and MLO-A5 cells support the 
action of these agents in protecting bone from resorption. Next, we examined their effects on 
4T1.2 mammary tumor cells. First, the result from an MTT cell proliferation assay revealed 
that these agents inhibited proliferation of 4T1.2 cells (Fig. 2A). The levels of p-eIF2α, a 
marker for integrated stress, cleaved caspase, an apoptosis marker, and LC3A/B II, an 
autophagy marker, were elevated (Fig. 2B-D). Of note, the elevation of the autophagy 
marker indicates induction of a pro-survival pathway along with induction of apoptosis. A 
Liu et al. Page 6
Cancer Res. Author manuscript; available in PMC 2019 July 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2D motility assay showed that both agents reduced the healing of the scratched wound in a 
dose-dependent manner at 1, 5 and 10 μM (Fig. 2E, Supplementary Fig. S2A&B).
Next, FP and TFP action through dopamine receptors was examined. RNA interference 
using Drd1 siRNA and Drd2 siRNA, two dopamine receptor genes, revealed that partial 
silencing of Drd2 significantly suppressed FP/TFP-induced inhibition of tumor proliferation 
and migration (Fig. 2F-H). Compared to the effect of Drd2 siRNA, that of Drd1 siRNA was 
less significant (Supplementary Fig. S2C-E). Using MDA-MB-231 breast cancer cells, we 
also confirmed that FP and TFP inhibited their proliferation (Supplementary Fig. S3A), 
elevated p-eIF2α, cleaved caspase 3, and LC3A/B II (Supplementary Fig. S3B), and 
decreased migration (Supplementary Fig. S3C). In MCF7 breast cancer cells, the same 
trends in proliferation (Supplementary Fig. S4A), protein expression (Supplementary Fig. 
S4B), and migration (Supplementary Fig. S4C) were observed. The result from the MTT 
cell proliferation assay was supported by an EdU cell proliferation assay, in which the 
relative proliferation rate of 4T1.2 cells, MDA-MB-231 cells, and MCF-7 cells was reduced 
by FP and TFP in a dose-dependent manner (Fig. 3A-C).
Expansion of the necrotic core in 4T1.2 spheroids by FP and TFP
We further examined the effects of these agents on tumor growth using 3D 4T1.2 tumor 
spheroids. We observed that the tumor spheroid developed a three-layered spherical structure 
composed of a necrotic core at the center, a quiescent shell around the necrotic core, and a 
proliferating zone on the surface (Fig. 3D). In response to 1, 5, and 10 μM FP and TFP, the 
necrotic core expanded along incubation time in a dose-dependent manner (Fig. 3D-F). 
Consistent with the expansion of the necrotic core, the luminescence level in the 3D viability 
assay was decreased by drug treatment (Fig. 3G), associated with an increased level of 
cleaved caspase 3 (Fig. 3H).
Suppression of tumor growth and bone loss in a mouse model
After examining the actions of FP and TFP on bone cells and tumor cells in monolayer cell 
cultures and in 3D spheroids, we conducted in vivo analysis using mouse models of 
mammary tumor and bone metastasis. First, 4T1.2 cells were inoculated to the mammary fat 
pad, and development of the mammary tumor was monitored (Fig. 4A-D). The results 
revealed that the size and weights of the tumors were significantly reduced by daily 
administration of FP or TFP. Second, we induced the migration of tumor cells into the right 
hind limb by injecting 4T1.2 cells into the right iliac artery. Using μCT images, we 
reconstructed the 3D structure of trabecular bone in the distal femur (Fig. 4E). Compared to 
placebo, FP- and TFP-treated samples presented a denser distribution of trabecular bone 
segments in the distal femur, with an increase in trabecular thickness (Fig. 4F). Compared to 
placebo, the bone volume was significantly higher in the FP-treated group but not in the 
TFP-treated group. In response to four-point bending mechanical test, the femur stiffness 
was greater in both FP- and TFP-treated groups (Fig. 4G).
Type I collagen is the most abundant protein in bone matrix. To evaluate the role of type I 
collagen in tumor growth and migration in the bone microenvironment, we co-injected type I 
collagen with 4T1.2 tumor cells into the left tibial cavity and conducted mechanical testing 
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and histological analysis. Mechanical testing revealed that compared to the contralateral 
tibia, tibial stiffness was significantly lowered after 2-3 weeks (Fig. 4H&I; Supplementary 
Fig. S5A). However, co-injection of collagen suppressed the reduction of stiffness. 
Histological analysis showed that co-injection of collagen facilitated scattering tumor cells 
throughout the tibial bone cavity by reducing their aggregation (Fig. 4J, Supplementary Fig. 
S5B).
Reduced Inhibitory Effects of FP and TFP by Interactions with RAW264.7 cells
The results so far indicate that the two agents in this study significantly alter the fate of 
tumor growth as well as bone remodeling. In order to understand the action of these agents 
in the bone microenvironment, we next examined interactions of 4T1.2 spheroids with 
RAW264.7 cells in the presence and absence of these agents. First, we evaluated indirect 
interactions using the conditioned medium isolated from RAW264.7 pre-osteoclast cells. 
RAW264.7 conditioned medium expanded the quiescent zone with an increase in live cells 
(Supplementary Fig. S6A). The 3D viability assay revealed that the conditioned medium 
elevated the number of live cells in the presence and absence of FP and TFP at 1 and 5 μM 
(Fig. 5A&B). In response to RAW264.7 pre-osteoclast-derived conditioned medium, 
expression of Snail, a transcription factor for inducing epithelial-to-mesenchymal transition 
(EMT), was upregulated (Fig. 5C). In a 3D co-culture, 4T1.2 cells did not mix with 
RAW264.7 cells, and they formed two separate spheroids (Supplementary Fig. S6B&C). In 
a spheroid fusion assay, 20 μM FP and TFP reduced the size of RAW264.7 spheroids.
Regulation of Snail and p-Akt by interactions with MLO-A5 cells
To further understand the interactions in the bone microenvironment, we examined 4T1.2 
spheroids with osteocytes. Incubation of 4T1.2 spheroids with conditioned medium from 
MLO-A5 osteocyte cells showed a decrease in surface roughness and an increase in relative 
proliferation (Fig. 5D&E, Supplementary Fig. S6D). Confocal microscopy of 4T1.2 
spheroids illustrated that, compared with control, MLO-A5-conditioned medium increased 
the number of Click-iT EdU-labeled dividing cells (Fig. 5E). Western blot analysis revealed 
that Snail was downregulated in 4T1.2 cells by MLO-A5-conditioned medium as well as FP 
and TFP (Fig. 5F-H). Of note, RAW264.7-conditioned medium elevated the protein level of 
Snail (Fig. 5C). However, the level of p-Akt was elevated by MLO-A5-conditioned medium 
and reduced by FP and TFP (Fig. 5F-H). The level of Snail was further reduced by 
simultaneous application of osteocyte-derived conditioned medium and FP/TFP (Fig. 5H). 
Unlike RAW264.7 cells, MLO-A5 cells freely mixed with 4T1.2 cells, and these two types 
of cells formed a single integrated spheroid (Fig. 5I). In the presence of MLO-A5 spheroid, 
the diameter of the 4T1.2 spheroid was slightly decreased, and administration of 20 μM FP 
and TFP further reduced the diameter (Fig. 5J).
Reduction in Snail by incubation with type I collagen
Osteocytes are surrounded by bone matrix, in which type I collagen is the most abundant 
protein. In response to MLO-A5-derived conditioned medium, downregulation of Snail and 
upregulation of p-Akt were sustained for 24 h (2, 3, 6, 12, and 24 h) (Fig. 6A). In order to 
evaluate the potential role of type I collagen in interactions of tumor spheroids with MLO-
A5 osteocytes or their conditioned medium, we cultured 4T1.2 tumor spheroids in the 
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presence of type I collagen at 0.1 to 10 μg/ml (Fig. 6B) and measured their protein 
expression in 2D culture (Fig. 6C). Compared to tumor spheroids in the control medium, the 
medium with type I collagen made spheroids smaller and more circular with smoother 
surfaces (Fig. 6B, D&E). Associated with those phenotypic alterations, Snail protein was 
downregulated, and 4T1.2 cells became less migratory in a dose-dependent manner (Fig. 6C, 
F&G). Furthermore, the protein levels of Zo-1, p-NFκB and p-Akt were elevated (Fig. 6C). 
In the wound healing assay, motility of 4T1.2 cells was reduced by collagen, FP, and TFP, 
and the simultaneous application of collagen with FP/TFP further suppressed the migratory 
behavior of tumor cells (Fig. 6F&G).
Partial suppression of A5 medium effects by Snail overexpression
The results so far show that direct and indirect interactions of tumor cells with osteocytes 
shrink tumor spheroid size and alter expression of Snail and Akt. Snail is downregulated by 
FP and TFP as well as tumor-osteocyte interactions. We further evaluated the role of Snail 
using a wound healing assay, in which migratory behaviors of 4T1.2 cells were suppressed 
by MLO-A5 conditioned medium (Fig. 7A&B). When Snail plasmid was transfected into 
4T1.2 cells to elevate its expression, Zo-1 is downregulated (Fig. 7C), and the surface of the 
tumor spheroids became rougher, regardless of treatment with MLO-A5 conditioned 
medium or FP/TFP (Fig. 7D&E). Furthermore, compared to the vector control, Snail 
overexpression partially suppressed A5 medium-driven inhibition of cellular motility (Fig. 
7F&G).
Discussion
This study presented that tumor-osteocyte interactions downregulated expression of Snail in 
4T1.2 tumor cells and reduced the migratory behavior of 3D tumor spheroids. The 
interactions also elevated DNA replication in the proliferating surface of tumor spheroids by 
activating NFκB and Akt pathways. Compared to MLO-A5 osteocyte cells, RAW264.7 pre-
osteoclast cells showed weaker affinity to tumor cells and Snail overexpression. Tumor-
osteocyte interactions as well as type I collagen suppressed the inhibitory effect of FP and 
TFP on the proliferation of tumor cells, while they enhanced FP/TFP’s suppression of tumor 
cell migration. Collectively, osteocytes appear to act as an attractant of tumor cells to the 
collagen-rich bone matrix, while osteoclasts act as a desensitizer of the action of FP and TFP 
on tumor cells in the 3D bone-like microenvironment. In the proposed mechanism (Fig. 7H), 
Drd2 and osteocytes both suppress Snail, but they have opposing effects on tumor 
proliferation markers Akt and NFκB. Collagen-rich osteocytes promote tumor cell 
aggregation, while Drd2 attenuates migratory tumor behavior.
FP is an antagonist of dopamine receptors D1 and D2, while TFP is an antagonist of D2 
dopamine receptor (32). TFP is also known to antagonize calmodulin (33). We have 
previously reported that A77636, a selective D1 dopamine receptor agonist, prevents tumor 
growth and bone resorption (17). It is reported that the role of D1 is opposite to that of D2, 
and thus an agonist of D1, like A77636, may exert the same effect of an antagonist of D2, 
like FP and TFP. We have previously reported that A77636’s action is in part mediated by 
the elevated phosphorylation of eIF2α (17). A77636 stimulated dopamine- and cAMP-
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regulated phosphoprotein (DARPP32) that inhibits protein phosphate 1 and elevates the level 
of p-eIF2α. Furthermore, elevated p-eIF2α was shown to suppress tumor cell migration via 
inhibition of Rac1 and prevent bone resorption via suppression of NFATc1. Consistent with 
our previous study, we have also observed dose-dependent upregulation of p-eIF2α in 4T1.2 
tumor cells and RAW264.7 pre-osteoclast cells by FP and TFP. In response to partial RNA 
silencing of Drd1 and Drd2, the result indicated that FP/TFP-driven suppression of 
proliferation and migration of tumor cells was mainly mediated by Drd2.
In evaluating interactions of tumor cells to MLO-A5 cells and RAW264.7 cells, we 
employed 3D spheroid assays as well as monolayer cell cultures with conditioned media. 
Experiments with conditioned media allowed us to evaluate the effects of secretory factors, 
while spheroid co-culturing and fusion led to evaluation of direct interactions more relevant 
to the physiological microenvironment than monolayer cultures. In response to FP and TFP, 
the necrotic core of tumor spheroids was enlarged, and ATP availability on the proliferating 
surface was reduced in a 3D viability assay. Unlike RAW264.7 cells, which did not fuse well 
with 4T1.2 cells, MLO-A5 cells fused with 4T1.2 cells to merge completely. Conditioned 
medium from RAW264.7 cells spread tumor spheroids and expanded the proliferating zone 
on the spheroid surface. The conditioned medium from MLO-A5 cells, however, reduced 
surface roughness and slightly shrank the tumor spheroids. Although tumor spheroid size 
was reduced by fusion with MLO-A5, MLO-A5-conditioned medium elevated DNA 
replication of the proliferating zone of tumor spheroids. Taken together, MLO-A5 cells 
appeared to capture and nurture tumor cells.
To understand the mechanism of action in tumor-osteocyte interactions, we evaluated the 
role of type I collagen, the most abundant protein in bone matrix and rich in osteocyte-
derived conditioned medium. We observed that type I collagen acted as an attractant and 
dwarfing agent of migratory tumor cells and converted them to less migratory, more 
proliferative cells. When collagen was heat-denatured, it lost its ability to attract migratory 
tumor cells. It is conceivable that interactions of type I collagen with tumor cells are 
mediated by integrins such as α1β1, α2β1, and α11β1, and other bone matrix proteins may 
assist interactions via binding to collagens (34). Consistent with in vitro results, histological 
analysis showed that co-injection of type I collagen with tumor cells promoted the mixing 
and scattering of tumor cells, diffusing through the bone marrow cavity to form small but 
widely spread clusters. Collagen co-injection also reduced the weakening of bone stiffness 
measured by in vivo mechanical testing.
Incubation with type I collagen downregulated Snail, a transcription factor involved in EMT, 
and upregulated Zo-1, p-Akt and p-NFκB. Snail is regulated by various signals at the level 
of transcription as well as post-translation (35). Zo-1 is associated with adhesion and tight 
junction linked cell-cell communication, while Akt and NFκB contribute to various 
mechanisms, including cellular proliferation. Bone matrix contains a variety of matrix 
proteins, and, in addition to type I collagen, the involvement of other proteins need to be 
evaluated. These results raise the possibility that matrix proteins, including type I collagen, 
may act as inducers of immobilization and proliferation of tumor cells in the bone 
microenvironment, which is commonly observed in MET (36), the reversal of EMT. Further 
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investigation of molecular and cellular behaviors of tumor cells is needed to understand the 
role of tumor-osteocyte interactions in MET.
Clinical reports on the usage of dopamine modulators on the risk of breast cancer vary. In 
~140,000 cases of dopamine-deficient Parkinson’s disease patients, administration of 
dopamine antagonist is shown to lower rates of breast cancer, even factoring in depression 
and suicide risk (37). In a separate study of ~53,000 cases, usage of dopamine antagonists 
increased the risk of breast cancer by 16% (38). In schizophrenia patients (~6,000 cases), 
results vary widely, ranging from 52% risk increase to 40% risk decrease (39). No clinical 
data are available for potential effects of FP and TFP on bone metastasis.
The results herein establish a link between bone cell secretions and tumor activity, though 
there are several limitations that should be noted. Dopamine receptor modulators FP and 
TFP and osteocyte-conditioned medium both reduced spheroid size and tumor migration, but 
they had opposing effects on cell proliferation. This study used mouse-derived cell lines of 
osteoblasts, osteoclasts, and osteocytes, as well as a triple-negative mammary tumor mouse 
cell line. Human cell lines as well as other breast cancer types should be used to translate 
these findings toward clinical relevance. Though these existing drugs are well-studied for 
use in psychiatric patients, their side effects must be carefully considered, or they might be 
selectively delivered to tumor cells. While FP and TFP were analyzed as antagonists to 
DRD2, these agents may have limited selectivity and interact with other DRDs.
Much previous work has shown the importance in osteoclast feedback with tumor cells in 
bone metastasis, but our work explores the role of osteocytes. This study demonstrates that 
tumor-osteocyte interactions decrease Snail expression and increase Akt and NFκB 
signaling in tumor cells, and those interactions alter the efficacy of dopamine-modulating FP 
and TFP. In the bone microenvironment, tumor-osteocyte interactions strengthen inhibition 
by FP and TFP on tumor migration but weaken their suppression of tumor proliferation. 
Furthermore, the result presents a mechanistic rationale for possible future research 
directions in using collagen-based or other osteocyte-derived secretory factors to capture or 
target metastatic tumor cells. Those factors might also be useful in disrupting the 
communication between osteocytes and metastatic tumor cells.
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Significance
Findings provide novel insight into the cellular cross talk in the bone microevironment 
and the effects of dopamine modulators on mammary tumor cells and osteocytes.
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Figure 1. 
Inhibition of proliferation and differentiation of RAW264.7 pre-osteoclast cells by 
Fluphenazine and Trifluoperazine. Of note, CN = control, FP = Fluphenazine, and TFP = 
Trifluoperazine. The single and double asterisks indicate p < 0.05 and p < 0.01, respectively, 
and the double hashtag marks p < 0.01 to the control in the absence of RANKL. (A&B) 
Reduction in cellular proliferation, and upregulation of p-eIF2α by Fluphenazine. (C) 
Downregulation of NFATc1 and Cathepsin K by Fluphenazine. (D&E) Reduction in cellular 
proliferation, and upregulation of p-eIF2α by Trifluoperazine. (F) Downregulation of 
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NFATc1 and Cathepsin K by Trifluoperazine. (G&H) Suppression of RANKL-driven 
osteoclastogenesis by Fluphenazine and Trifluoperazine, respectively. (I&J) Dose-dependent 
inhibition of cellular proliferation in 3D spheroids and a decrease in 3D cell viability by 
Trifluoperazine.
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Figure 2. 
Inhibitory effects of Fluphenazine and Trifluoperazine on proliferation and migration of 
4T1.2 mammary tumor cells. Of note, CN = control, FP = Fluphenazine, and TFP = 
Trifluoperazine. The single and double asterisks indicate p < 0.05 and p < 0.01, respectively. 
(A) Reduced proliferation of 4T1.2 cells in response to Fluphenazine or Trifluoperazine. (B) 
Elevation of p-eIF2α by Fluphenazine and Trifluoperazine. (C) Representative cell images 
in response to 5 μM Fluphenazine or Trifluoperazine. The arrow indicates apoptotic cells, 
while the arrow head marks autophagic cells. (D) Elevation of the cleaved caspase 3 (marker 
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for apoptosis) and Lc3A/B II (marker for autophagy) in response to Fluphenazine or 
Trifluoperazine. (E) Retarded migration of 4T1.2 cells by 1, 5 or 10 μM Fluphenazine in a 
dose dependent manner. (F-H) Suppression of the inhibitory effect of Fluphenazine and 
Trifluoperazine on proliferation and migration by RNA silencing with Drd2 siRNA.
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Figure 3. 
Responses of tumor cells (4T1.2 cells, MDA-MB-231 cells, and MCF7 cells) to 
Fluphenazine and Trifluoperazine. Of note, CN = control, FP = Fluphenazine, and TFP = 
Trifluoperazine. The single and double asterisks indicate p < 0.05 and p < 0.01, respectively. 
(A-C) EdU-based relative proliferation of 4T1.2 cells, MDA-MB-231 cells, and MCF cells, 
respectively. (D) Temporal alterations in morphology of 4T1.2 spheroids in response to 1, 5, 
and 10 μM Fluphenazine in 24, 48, 72, 94, and 120 h. (E&F) Increased relative area of the 
necrotic core by Fluphenazine and Trifluoperazine, respectively. (G) Decrease in 3D cell 
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viability by 10 and 20 μM Trifluoperazine. (H) Elevation of the cleaved caspase 3 (marker 
for apoptosis) and Lc3A/B II (marker for autophagy) in response to Trifluoperazine.
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Figure 4. 
Effects of Fluphenazine, Trifluoperazine, and collagen in a mouse model of mammary tumor 
and bone metastasis. Of note, FP = Fluphenazine, and TFP = Trifluoperazine. The single 
asterisk indicates p < 0.05. (A&B) Suppression of tumor growth at the mammary pad by 
Fluphenazine. (C&D) Suppression of tumor growth at the mammary pad by Trifluoperazine. 
(E) Reconstructed 3D μCT images of the distal femur for the placebo, Fluphenazine-treated, 
and Trifluoperazine-treated samples. (F) Trabecular thickness and bone volume. (G) Femur 
stiffness in four-point bending mechanical test. (H&I) Suppression of reduction in bone 
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stiffness by co-injection of collagen into the tibia. (J) Scattered distribution of 4T1.2 tumor 
cells (highlighted in red) in the tibial bone cavity and smaller average tumor cluster size by 
co-injection of collagen.
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Figure 5. 
Effects of RAW264.7 osteoclast-conditioned medium and MLO-A5 osteocyte-conditioned 
medium on 4T1.2 spheroids in the presence and absence of Fluphenazine or Trifluoperazine. 
Of note, CN = control, FP = Fluphenazine, and TFP = Trifluoperazine. The single and 
double asterisks indicate p < 0.05 and p < 0.01, respectively. (A&B) Alteration in 3D cell 
viability of 4T1.2 spheroids by the conditioned medium from RAW264.7 cells. (C) 
Upregulation of Snail protein by RAW264.7 conditioned medium. (D) Roughness of 4T1.2 
spheroids in response to Fluphenazine or Trifluoperazine. (E) 3D cell viability and relative 
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proliferation of 4T1.2 spheroids in response to Fluphenazine or Trifluoperazine. (F-H) 
Alterations in Snail and p-Akt in response to MLO-A5 conditioned medium, Fluphenazine, 
and/or Trifluoperazine. (I) Interactions of 4T1.2 cells (green) and MLO-A5 cells (red). 
These two types of cells completely mixed. (J) Shrinkage of 4T1.2 spheroids (red) by 20 μM 
Fluphenazine or Trifluoperazine in the presence of MLO-A5 spheroids (green). The size of 
4T1.2 spheroids (red) was significantly reduced by Fluphenazine or Trifluoperazine.
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Figure 6. 
Effect of collagen on tumor spheroids and cellular motility. (A) Effects of MLO-A5-derived 
conditioned medium on expression of Snail, p-NFκB, and p-Akt. (B) 4T1.2 tumor spheroids 
in response to collagen in the medium. (C) Effects of collagen on expression of Snail, p-
NFκB, and p-Akt. (D&E) Effects of collagen on spheroid cross-sectional area and surface 
roughness. (F&G) Reduction in cellular motility of 4T1.2 cells by type I collagen and/or FP/
TFP.
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Figure 7. 
Effects of upregulated Snail expression in 4T1.2 cells. Of note, CN = control, A5 = MLO-
A5 osteocyte-like cells, FP = Fluphenazine, and TFP = Trifluoperazine. The single and 
double asterisks indicate p < 0.05 and p < 0.01, respectively. (A&B) Retarded migration of 
4T1.2 cells by MLO-A5 conditioned medium. (C) Upregulation of Snail expression by 
transfection of Snail plasmid. (D&E) Effects of transfection of Snail plasmid on surface 
roughness. (F&G) Partial suppression of A5-conditioned medium driven reduction in 
migration by transfection of Snail plasmid. (H) Proposed mechanism of tumor-osteocyte 
Liu et al. Page 27
Cancer Res. Author manuscript; available in PMC 2019 July 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interactions with Drd2 inhibitors. FP and TFP, inhibitors of Drd2, reduce Snail expression, 
osteoclast activity, Akt and NFκB proliferation markers, and tumor cell migration. Osteocyte 
interaction reduces Snail expression and cell migration, but increases Akt and NFκB 
expression.
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